{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T15:02:22Z","timestamp":1775746942526,"version":"3.50.1"},"reference-count":11,"publisher":"Walter de Gruyter GmbH","issue":"5","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2018,5,24]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_jpem-2017-0458_s_999_w2aab3b7c26b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background:<\/jats:title>\n                  <jats:p>Provocative growth hormone (GH) stimulation testing is used to evaluate short stature and growth failure in children. Agents commonly used for testing include clonidine, arginine and glucagon. While stimulation testing is generally considered safe, gross hematuria has been described as a rare idiopathic complication of GH stimulation testing. This study was designed to estimate the incidence of both microscopic and macroscopic hematuria following GH testing with different provocative agents.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2017-0458_s_998_w2aab3b7c26b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods:<\/jats:title>\n                  <jats:p>Subjects undergoing GH stimulation testing were invited to participate in the study. Prior to testing, vital signs were measured and baseline point-of-care (POC) urinalysis was done. The subjects performed urine testing at home on days 1, 2, 3 and 7 following GH stimulation studies. Families notified the study team with any positive findings and returned the data collection tool by mail.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2017-0458_s_997_w2aab3b7c26b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results:<\/jats:title>\n                  <jats:p>In total, 34 subjects aged 11.14\u00b12.71 years (91.2% male) completed the study. Agents used in provocative testing included arginine (73.5%), clonidine (94.1%) and glucagon (32.4%). Three subjects developed hematuria after GH stimulation testing (clonidine\/arginine). The hematuria resolved by 7 days after testing. Additional adverse effects included nausea, vomiting and hypotension.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_jpem-2017-0458_s_996_w2aab3b7c26b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions:<\/jats:title>\n                  <jats:p>In this study of children undergoing GH testing, hematuria was identified in three subjects. This study demonstrates that side effects to agents used for GH testing are self-limited, yet not rare, and should be discussed with patients and families prior to stimulation testing.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/jpem-2017-0458","type":"journal-article","created":{"date-parts":[[2018,4,24]],"date-time":"2018-04-24T22:15:51Z","timestamp":1524608151000},"page":"539-543","source":"Crossref","is-referenced-by-count":4,"title":["Hematuria as an adverse outcome following provocative growth hormone stimulation testing in children"],"prefix":"10.1515","volume":"31","author":[{"given":"Rajeev","family":"Thirunagari","sequence":"first","affiliation":[{"name":"Division of Pediatric Endocrinology , Children\u2019s Hospital of Michigan , Detroit, MI , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Marrone","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology , UBMD Pediatrics , Buffalo, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hannah","family":"Elsinghorst","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology , UBMD Pediatrics , Buffalo, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lucy D.","family":"Mastrandrea","sequence":"additional","affiliation":[{"name":"Division of Pediatric Endocrinology , Children\u2019s Hospital of Michigan , Detroit, MI , USA"},{"name":"Division of Pediatric Endocrinology , UBMD Pediatrics , Buffalo, NY , USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"374","published-online":{"date-parts":[[2018,4,24]]},"reference":[{"key":"2021021322190717572_j_jpem-2017-0458_ref_001_w2aab3b7c26b1b6b1ab2b2b1Aa","doi-asserted-by":"crossref","unstructured":"Chesover AD, Dattani MT. Evaluation of growth hormone stimulation testing in children. Clin Endocrinol 2016;84:708\u201314.","DOI":"10.1111\/cen.13035"},{"key":"2021021322190717572_j_jpem-2017-0458_ref_002_w2aab3b7c26b1b6b1ab2b2b2Aa","doi-asserted-by":"crossref","unstructured":"Molitch ME, Clemmons DR, Malozowski S, Merriam GR, Vance ML. Evaluation and treatment of adult growth hormone deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab 2011;96:1587\u2013609.","DOI":"10.1210\/jc.2011-0179"},{"key":"2021021322190717572_j_jpem-2017-0458_ref_003_w2aab3b7c26b1b6b1ab2b2b3Aa","doi-asserted-by":"crossref","unstructured":"Grimberg A, DiVall SA, Polychronakos C, Allen DB, Cohen LE, et al. Guidelines for growth hormone and insulin-like growth factor-I treatment in children and adolescents: growth hormone deficiency, idiopathic short stature, and primary insulin-like growth factor-I deficiency. Horm Res Paediatr 2016;86:361\u201397.","DOI":"10.1159\/000452150"},{"key":"2021021322190717572_j_jpem-2017-0458_ref_004_w2aab3b7c26b1b6b1ab2b2b4Aa","doi-asserted-by":"crossref","unstructured":"Marinkovic M, Newfield Ron S. Self-limiting hematuria following growth hormone provocative testing with arginine hydrochloride. J Pediatr Endocrinol Metab 2012;25:791\u20133.","DOI":"10.1515\/jpem-2012-0160"},{"key":"2021021322190717572_j_jpem-2017-0458_ref_005_w2aab3b7c26b1b6b1ab2b2b5Aa","doi-asserted-by":"crossref","unstructured":"Uetrecht J, editor. Adverse drug reactions: handbook of experimental pharmacology, Vol. 196. Berlin, Heidelberg: Springer-Verlag, 2010:111\u201330.","DOI":"10.1007\/978-3-642-00663-0"},{"key":"2021021322190717572_j_jpem-2017-0458_ref_006_w2aab3b7c26b1b6b1ab2b2b6Aa","unstructured":"R-GENE-arginine hydrochloride injection, solution, Pharmacia and Upjohn, Company; Available at: http:\/\/labeling.pfizer.com\/ShowLabeling.aspx?id=642. Accessed 5 Oct 2017."},{"key":"2021021322190717572_j_jpem-2017-0458_ref_007_w2aab3b7c26b1b6b1ab2b2b7Aa","unstructured":"Kuczmarski RJ, Odgen CL, Guo SS, Grummer-Strawn LM, Flegal KM, et al. 2000 CDC Growth Charts for the United States: methods and devlopment. Vital Health Stat 2002;11:1\u2013190."},{"key":"2021021322190717572_j_jpem-2017-0458_ref_008_w2aab3b7c26b1b6b1ab2b2b8Aa","unstructured":"Available at: https:\/\/zscore.research.chop.edu\/. Accessed 5 Oct 2017."},{"key":"2021021322190717572_j_jpem-2017-0458_ref_009_w2aab3b7c26b1b6b1ab2b2b9Aa","unstructured":"Ghigo E, Bellone J, Aimaretti G, Bellone S, Loche S, et al. Reliability of provocative tests to assess growth hormone secretory status. Study in 472 normally growing children. J Clin Endocrinol Metab 1996;81:3323\u20137."},{"key":"2021021322190717572_j_jpem-2017-0458_ref_010_w2aab3b7c26b1b6b1ab2b2c10Aa","doi-asserted-by":"crossref","unstructured":"Yuste C, Gutierrez E, Sevillano AM, Rubio-Navarro A, Amaro-Villalobos JM, et al. Pathogenesis of glomerular haematuria. World J Nephrol 2015;4:185\u201395.","DOI":"10.5527\/wjn.v4.i2.185"},{"key":"2021021322190717572_j_jpem-2017-0458_ref_011_w2aab3b7c26b1b6b1ab2b2c11Aa","doi-asserted-by":"crossref","unstructured":"Fiseha T, Tamir Z. Urinary markers of tubular injury in early diabetic nephropathy. Int J Nephrol 2016; Article ID: 4647685.","DOI":"10.1155\/2016\/4647685"}],"container-title":["Journal of Pediatric Endocrinology and Metabolism"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/jpem.2018.31.issue-5\/jpem-2017-0458\/jpem-2017-0458.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2017-0458\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2017-0458\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,22]],"date-time":"2021-04-22T01:43:28Z","timestamp":1619055808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/jpem-2017-0458\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,4,24]]},"references-count":11,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2018,4,24]]},"published-print":{"date-parts":[[2018,5,24]]}},"alternative-id":["10.1515\/jpem-2017-0458"],"URL":"https:\/\/doi.org\/10.1515\/jpem-2017-0458","relation":{},"ISSN":["2191-0251","0334-018X"],"issn-type":[{"value":"2191-0251","type":"electronic"},{"value":"0334-018X","type":"print"}],"subject":[],"published":{"date-parts":[[2018,4,24]]}}}